Generex Biotechnology Corporation Announces That Its Protocol for Metcontrol, the Company's Proprietary Metformin Chewing Gum Product, Will Be Submitted to Regulatory Agencies for the Conduct of a Clinical Study

Published: Mar 12, 2008

WORCESTER, Mass., March 12, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has finalized the protocol for Metcontrol(tm), the Company's proprietary Metformin chewing gum product, and will be proceeding with applications to regulatory agencies for approval of the protocol for a clinical study. The protocol is an Open-Label Crossover Study comparing Generex's Metformin chewing gum and immediate release tablets in healthy volunteers.

Back to news